Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Dual Phase 1/2, Investigator Initiated Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of 186Rhenium Nanoliposomes (186RNL) in Recurrent Glioma (CTRC 12-02)

Next Previous
Trial Profile

A Dual Phase 1/2, Investigator Initiated Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of 186Rhenium Nanoliposomes (186RNL) in Recurrent Glioma (CTRC 12-02)

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 21 Aug 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rhenium (186Re) obisbemeda (Primary)
  • Indications Astrocytoma; Diffuse intrinsic pontine glioma; Ependymoma; Glioblastoma; Glioma
  • Focus Adverse reactions; First in man; Registrational; Therapeutic Use
  • Acronyms ReSPECT; ReSPECT-GBM; ReSPECT-TM
  • Sponsors Cerenome

Most Recent Events

  • 31 Jul 2026 According to the Plus Therapeutics media release, Plus Therapeutics is now called Cerenome.
  • 30 Jun 2026 According to the Plus Therapeutics Media Release, ReSPECT-GBM, has enrolled 31 of the target 34 subjects. Current enrollment rates support full enrollment in 2026 at 3 active sites. Following completion of the current study and an end-of-Phase 2 meeting with the FDA, the Company believes it may be positioned to move toward a registration study, subject to the final clinical data and related business considerations.
  • 15 May 2026 According to the Plus Therapeutics Media Release, the enrollment completion expected in 2026; data from this trial expected in Q1 2027 and company plans to conduct End of Phase meeting with FDA

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top